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Joint association of polymorphism of the FGFR4 gene and
mutation TP53 gene with bladder cancer prognosis
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The impact of the fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism on bladder cancer is unknown. We found
no clear correlations between the FGFR4 genotype and risk of bladder cancer or pathological parameters. Neither the polymorphism
nor TP53 mutation status was an independent predictor of prognosis, but they might act jointly on the disease-specific survival of
patients.
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Bladder cancer is the fourth most common cancer in men and the
ninth most common cancer in women in the United States. In
2006, there will be 61 420 new cases diagnosed and 13 060 will die
from the disease (American Cancer Society, 2006). Owing to the
highly heterogeneous clinical behaviors of bladder carcinoma,
there is a need to stratify patients by molecular markers to
optimise management and improve survival for patients with
bladder cancer.
The fibroblast growth factor receptor (FGFR) family, which
comprises of four structurally related tyrosine kinase receptors,
transduces various crucial biological activities required for the
growth and survival of cancer cells (Powers et al, 2000). Mutations
in the FGFR3 gene have been identified in 40– 50% of bladder
tumours, and were associated with a favourable prognosis with a
lower recurrence rate and disease-specific mortality (Cappellen
et al, 1999; Karoui et al, 2001; Sibley et al, 2001; van Rhijn et al,
2001). These mutations in the FGFR3 gene are largely bladder
cancer specific, and it is suggested that the FGFR family may play
an important role in bladder carcinogenesis.
Recently, a common polymorphism in the transmembrane
domain of the FGFR4 gene, Gly388Arg, was identified by Bange’s
group (Bange et al, 2002). A positive correlation between the
presence of the FGFR4 Arg388 allele and prognostic parameters as
well as survival time was reported in variant cancer studies,
including breast, colon, lung, prostate, head and neck cancers and
high-grade soft-tissue sarcoma (Bange et al, 2002; Morimoto et al,
2003; Streit et al, 2004; Wang et al, 2004; Spinola et al, 2005a).
However, most studies were carried out with a relatively small
sample size or suggested a possible effect only on a specific tumour
type (Morimoto et al, 2003) or population (Wang et al, 2004).
Furthermore, in subsequent larger studies of melanoma, breast,
and colon cancer, no obvious association between the Gly388Arg
genotype and cancer prognosis was found (Becker et al, 2003;
Jezequel et al, 2004; Spinola et al, 2005b; Streit et al, 2006).
Mutations in the FGFR3 and TP53 genes are the two most
frequent events observed in primary bladder tumours and have
occurred in 59% and 25% of tumours, respectively (van Rhijn et al,
2004). TP53 mutations are often found in advanced tumours and,
thus, are associated with a poor prognosis. On the contrary, FGFR3
mutations are associated with low-grade tumours and a favourable
prognosis. This mutually exclusive expression suggests that FGFR3
and TP53 gene mutations may represent two alternative genetic
pathways in the pathogenesis of bladder cancer.
To our knowledge, no study has been conducted on the
prognostic significance of the FGFR4 genotype in bladder cancer.
Given the potential involvement of the FGFR family in bladder
carcinogenesis, it is of interest to investigate the potential impact
of the FGFR4 Gly388Arg polymorphism and the combination of
the FGFR4 genotype and TP53 mutation status on the progression
of bladder cancer.
MATERIALS AND METHODS
This study involved 140 newly diagnosed bladder cancer patients
who underwent radical cystectomy and 151 healthy controls at the
Memorial Sloan-Kettering Cancer Center from October 1993 to
June 1997. All cancer patients were pathologically confirmed and
staged according to the TNM staging system. After obtaining IRB-
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approved signed consents, all subjects were interviewed and had
blood samples collected. Complete follow-up data were available
for 140 cases with a median follow-up time of 33 months (range,
5–120 months). Genotyping of the FGFR4 Gly388Arg polymorph-
ism was determined with the RFLP analysis as described by Bange
et al (2002). The status of TP53 mutation was previously detected
in the same samples by three essays, including manual sequencing,
a commercial genechip-based assay (p53 Genechip) and immuno-
histochemistry (Lu et al, 2002). The survival time was calculated
from the date of cystectomy to the date of disease-specific deaths,
the date of recurrence or metastasis, or the date of the last follow-
up. Survival curves were plotted according to the Kaplan–Meier
estimate and compared using the long-rank test. The proportional
hazards model was employed to estimate hazard ratios when
adjusting for potential confounding factors. All statistic analyses
were performed using SAS 8.1 software.
RESULTS
The present study comprised of 140 bladder cancer patients and
151 healthy controls. Fifteen patients were excluded from the
analysis because of poor quality DNA or indistinct genotyping
results. One hundred and twenty-five patients who had similar
distributions of demographic or pathological factors as the whole
study group were included in the analyses. Among the 125 bladder
cancer patients, 42.4% were heterozygous and 10.4% were
homozygous carriers of the Arg388 allele. Compared with
noncarriers, the OR of developing bladder cancer among Arg388
allele carriers was 1.05 (95% CI, 0.5–2.1) (data not shown). No
obvious correlation was observed between the FGFR4 Gly388Arg
polymorphism and clinicopathological parameters (Table 1).
Of the 125 patients who were treated with radical cystectomy, 98
patients died during the 120-month follow-up period. Seventy
three per cent of all deaths (n¼ 72) were due to bladder cancer. No
obvious difference was found between the FGFR4 genotype or
TP53 mutations and the disease-specific survival (Table 2). The
combination of both markers, however, was strongly associated
with the disease-specific survival. FGFR4 Gly388 homozygous
patients with TP53 mutation (median survival time¼ 14.2 months)
had a hazard ratio of 1.85 (95% CI, 1.01–3.39) for disease-specific
survival compared with the reference group, which consisted of
Gly388 homozygote without TP53 mutation and Arg388 allele
carriers with or without TP53 mutation. (median survival
time¼ 23.3, 23.9 and 31.5 months, respectively) (Figure 1B).
The FGFR4 Gly/Gly genotype was associated with poor
recurrence-free survival (P¼ 0.036, Figure 2A), but not metasta-
sis-free survival (P¼ 0.351, Figure 2B). Due to the small proportion
of patients who suffered the recurrence of bladder cancer during
the follow-up period, we combined recurrence and metastasis and
calculated the disease-free survival time for each case. After
adjusting for age, gender and pathologic stage, patients with the
Gly/Gly genotype or TP53 mutation had a similar disease-free
survival as Arg388 allele carriers (adjusted HR¼ 0.99 and 1.01,
respectively; data not shown).
DISCUSSION
We observed no clear association between the Gly388Arg genotype
and risk of bladder cancer, indicating that this SNP may not be
involved in the early development of bladder cancer. Our finding is
in agreement with several previous studies on other types of cancer
(Bange et al, 2002; Morimoto et al, 2003; Spinola et al, 2005a),
except for one study on prostate cancer (Wang et al, 2004).
The present study found no clear correlation between the FGFR4
Gly388Arg polymorphism and pathological parameters. Further-
more, our results did not directly indicate that either the FGFR4
genotype or TP53 mutation status was an independent predictor of
Table 1 Associations between the FGFR4 genotype and demographic
characteristics, smoking status, pathological parameters, and TP53 mutation
status in 125 patients with bladder cancer
Gly/Gly,
n (%)
Gly/Arg,
n (%)
Arg/Arg,
n (%) P-value
All patients 59 (47.2) 53 (42.4) 13 (10.4)
Age at diagnosis
(years7s.d.)
67.079.6 64.7710.9 69.779.5 0.220
Age(years)
466 35 (59.3) 29 (54.7) 8 (61.5) 0.868
r66 24 (40.7) 24 (45.3) 5 (38.5)
Gender
Male 45 (76.3) 42 (79.3) 10 (76.9) 0.952
Female 14 (23.7) 11 (20.7) 3 (23.1)
Smoking status
Current 7 (13.2) 7 (14.6) 1 (7.7) 0.885
Former 36 (67.9) 32 (66.7) 8 (61.5)
Never 10 (18.9) 9 (18.7) 4 (30.8)
Stage
I 4 (6.8) 3 (5.7) 1 (7.7) 0.993
II 5 (8.5) 5 (9.4) 1 (7.7)
III 45 (76.2) 41 (77.4) 11 (84.6)
IV 5 (8.5) 4 (7.5) 0 (0)
Grade
G1 3 (5.2) 3 (5.8) 0 (0) 0.924
G2 9 (15.5) 11 (21.1) 2 (15.4)
G3-4 46 (79.3) 38 (73.1) 11 (54.6)
Lymph node involvement
Present 22 (37.3) 22 (41.5) 7 (53.8) 0.545
Absent 37 (62.7) 31 (58.5) 6 (46.2)
Vascular invasion
Yes 31 (52.5) 27 (50.9) 8 (61.5) 0.842
No 28 (47.5) 26 (49.1) 5 (38.5)
TP53 mutation
Yes 26 (44.1) 22 (41.5) 10 (76.9) 0.076
No 33 (55.9) 31 (58.5) 3 (23.1)
Table 2 Hazard ratios of death from bladder cancer for the FGFR4
Gly388 polymorphism and TP53 mutation status in 125 cancer patients
No. Death
Death
(%)
Hazard
ratioa 95% CI P-value
FGFR4 genotype
Gly/Gly 59 38 64 1.42 (0.83–2.40) 0.198
Arg/Arg+Arg/Gly 66 34 52 ref.
TP53 status
Abnormal 62 38 61 1.53 (0.88–2.65) 0.133
Normal 63 34 54 ref.
FGFR4/TP53
Gly/Gly/abnormal 28 21 75 2.25 (1.04–4.88) 0.039
Gly/Gly/normal 31 17 55 1.28 (0.58–2.83) 0.538
Arg/Arg+Arg/Gly/
abnormal
34 17 50 1.38 (0.63–3.04) 0.423
Arg/Arg+Arg/Gly/
normal
32 17 53 ref.
Gly/Gly+abnormal 28 21 75 1.85 (1.01–3.39) 0.046
Other 97 51 53 ref.
aHazard ratios were adjusted for age, gender, lymph node involvement, tumour stage
and grade.
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prognosis for bladder cancer but that they might act jointly on the
disease-specific survival of patients, which supports the hypothesis
that the FGFR3 and TP53 gene mutations may represent two
alternative genetic pathways in the progression of bladder cancer
(van Rhijn et al, 2004). A trend showed a better disease-specific
survival rate for bladder cancer patients with the Arg/Arg
genotype. This is contrary to the findings of previous studies on
other types of cancer that the presence of the Arg allele is
associated with poor survival (Bange et al, 2002; Morimoto et al,
2003; Streit et al, 2004; Wang et al, 2004; Spinola et al, 2005a). The
reason for the conflicting results is unclear, but may reflect a
tissue-specific effect of this polymorphism. For example, the
activating somatic mutations in the FGFR3 gene appear to be
bladder specific, and a much lower frequency of the mutations of
the FGFR3 has been observed in other cancer sites. (Sibley et al,
2001; van Rhijn et al, 2001). The FGFR4 Gly388Arg polymorphism
results in an amino-acid change in the transmembrane domain,
which is a highly conserved region for receptor tyrosine kinase.
Analogous missense mutations in the transmembrane domain in
the FGFR3 gene, resulting from a Gly to Arg substitution at codon
380, were proposed to result in constitutive activation of FGFR3
signaling (Webster and Donoghue, 1996). In general, activating
FGFR3 mutations are associated with favourable disease char-
acteristics such as low stage and grade, low recurrence rate, and a
lower mortality rate (Sibley et al, 2001; van Rhijn et al, 2001).
Therefore, the FGFR4 Gly388 allele, but not the Arg388 allele, could
exert an effect on the aggressive behaviors of the cancer cells in
bladder.
We also found that the patients with the Gly/Gly genotype were
associated with a greater risk of recurrence, but were not
associated with metastasis compared with Arg allele carriers. Our
results are in accordance with a study of melanoma patients, which
showed no correlation between the FGFR4 genotype and
metastasis (Streit et al, 2006). One possible reason for positive
result in recurrence could possibly be due to false positives based
on a relatively small number of recurrence cases (less than 10%).
Although the finding of differences in survival rates according to
the combination of the FGFR4 genotype and TP53 mutation status
is interesting, the results should be interpreted with caution.
Because our study was limited to patients who underwent radical
cystectomy, which is the standard treatment for muscle invasive
bladder cancer (T2 –T4), there are more patients with higher
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Figure 1 Kaplan–Meier disease-specific survival curves of bladder cancer
patients. (A) Comparison between patients with FGFR4 Gly/Gly genotype
and patients with FGFR4 Arg/Arg or Arg/Gly genotypes. The curves of Gly/
Gly (n¼ 59) and Arg allele carrier (n¼ 66) patients are shown as solid and
dashed lines, respectively. (B) Based on the combination of the FGFR4
genotype and TP53 mutations status, comparison between Gly allele
homozygotes with abnormal p53 status (n¼ 28, solid) and other (n¼ 97,
dashed). Small dots indicate censored observations. P-values were
calculated by the log-rank test.
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Figure 2 Survival of patients with bladder cancer according to variants of
the FGFR Gly388Arg polymorphism. Log-rank analyses of the association
between FGFR4 genotypes and (A) recurrence-free survival time and (B)
metastasis-free survival time in bladder cancer.
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staging and grading tumours that have been recruited. However,
no strong association between the FGFR4 genotype and indicators
for the aggressive tumour was found in our study population
because of potential selection bias.
In summary, our results suggest that the variations in neoplastic
progression not only depends on somatic mutations occurring in
the tumour itself but also on the patient’s genetic characteristics.
However, the molecular mechanisms of the FGFR4 Gly388Arg
polymorphism has not been examined in human bladder
cancer. Information on the function of this polymorphism or its
potential biological interaction with TP53 is needed and may
add information to optimise the treatment of patients with
bladder cancer.
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